Immunic (NASDAQ:IMUX) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Immunic (NASDAQ:IMUX) from a sell rating to a hold rating in a research report released on Wednesday morning.

A number of other research firms also recently commented on IMUX. D. Boral Capital reiterated a “buy” rating and issued a $17.00 price objective on shares of Immunic in a report on Wednesday, February 26th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Immunic in a research note on Friday, February 21st. One analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $12.67.

Immunic Stock Performance

IMUX opened at $1.16 on Wednesday. Immunic has a one year low of $0.92 and a one year high of $2.11. The company has a market cap of $104.49 million, a P/E ratio of -0.94 and a beta of 1.89. The business’s 50-day simple moving average is $1.05 and its 200-day simple moving average is $1.23.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Immunic by 90.0% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company’s stock worth $205,000 after acquiring an additional 96,894 shares during the period. Millennium Management LLC lifted its position in Immunic by 480.6% during the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock worth $580,000 after acquiring an additional 479,846 shares during the period. Focus Partners Wealth lifted its position in Immunic by 1.1% during the 4th quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock worth $2,168,000 after acquiring an additional 23,610 shares during the period. Bridgeway Capital Management LLC lifted its position in Immunic by 11.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock worth $215,000 after acquiring an additional 22,200 shares during the period. Finally, 683 Capital Management LLC lifted its position in Immunic by 2.2% during the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock worth $700,000 after acquiring an additional 15,349 shares during the period. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.